RESUMO
BACKGROUND AND OBJECTIVE: The purpose of this quality management study was to demonstrate how one hospital made a journey from average patient experience to become a regional leader in the experience of patient care for nationally recognized quality and safety metrics. METHODS: Saint Francis Hospital & Medical Center (SFHMC) located in Hartford, Connecticut, serves a diverse sociodemographic community as part of Trinity Health. "Recommend the Hospital" (RTH) has been the main marker of patient experience at SFHMC and Trinity Health across the United States as part of the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS). From 2010 to 2019, SFHMC implemented unit-based rounding hospital-wide, adopting charge nurse and executive leadership rounding as standard work. The intense support from senior leadership spurred the implementation of these changes across middle management and all frontline workers. The t test was used to determine differences between the mean RTH scores between SFHMC, Connecticut, and the United States. RESULTS: Patient experience at SFHMC was regularly assessed by Press Ganey surveys and HCAHPS, which demonstrated higher scores than averages for the state of Connecticut and the United States between 2010 and 2019 (both Ps < .001). SFHMC was the top performer with an RTH score of 83%, with the state average being 71% and the national average being 72%. In the years following the implementation of a multipronged low-cost strategy, hospital RTH scores rose linearly from the state and national average. SFHMC observed gains in patient safety and quality scores as measured by national benchmarks, including Leapfrog patient safety scores of 7 A's and 1 B over a 4-year period. SFHMC was the only hospital in Connecticut to receive an A grade 4 years in a row. CONCLUSION: A combination of nurse-led, unit-based rounding and executive team rounding with a consistent focus on patient experience resulted in significant improvement in RTH scores for a busy teaching urban hospital, with only a modest investment of resources. There was also improvement in quality and safety outcomes, which together with patient experience of care drove fiscal stability in an increasingly value-based health care environment.
Assuntos
Segurança do Paciente , Satisfação do Paciente , Hospitais Urbanos , Humanos , Avaliação de Resultados da Assistência ao Paciente , Atenção Terciária à Saúde , Estados UnidosRESUMO
BACKGROUND: Three cases of anaphylactoid syndrome of pregnancy developed in association with the use of intracervical dinoprostone for cervical ripening. CASES: All cases occurred at our institution between October 1996 and February 2001. The patients developed respiratory symptoms shortly after placement of 0.25 mg of intracervical dinoprostone gel. Hemodynamic changes, manifested by tetanic uterine contractions and fetal heart rate decelerations, followed. Subsequently all 3 patients developed disseminated intravascular coagulation, characterized by severe hypofibrinogenemia. CONCLUSION: There appears to be an association between intracervical dinoprostone for cervical ripening and anaphylactoid syndrome of pregnancy. Clinicians utilizing this route of dinoprostone administration should be familiar with this rare but potentially life-threatening complication.
Assuntos
Anafilaxia/induzido quimicamente , Maturidade Cervical/efeitos dos fármacos , Dinoprostona/efeitos adversos , Dinoprostona/uso terapêutico , Coagulação Intravascular Disseminada/etiologia , Ocitócicos/efeitos adversos , Ocitócicos/uso terapêutico , Administração Tópica , Adulto , Dinoprostona/administração & dosagem , Feminino , Frequência Cardíaca Fetal , Humanos , Pessoa de Meia-Idade , Ocitócicos/administração & dosagem , Gravidez , SíndromeRESUMO
OBJECTIVE: To develop normative data for nasal bone length between 11 and 20 weeks' gestation and to assess the utility of nasal bone hypoplasia in the detection of fetal aneuploidy in the second trimester. METHODS: Well-dated, nonanomalous fetuses were examined between 11 and 20.9 weeks' gestation. The nasal bone was assessed and measured, and normative data from 11 to 20 weeks' gestation were determined. The nasal bone lengths in fetuses with confirmed aneuploidy were compared with the normative data. RESULTS: The fetal nasal bone length increased linearly with advancing gestational age. Nomograms including the 10th, 50th, and 90th percentiles were created. Nasal bone hypoplasia was seen in 6 of 6 cases of fetal trisomy in the second trimester. CONCLUSIONS: Nasal bone hypoplasia in the early second trimester identifies a cohort of fetuses at high risk for aneuploidy.
Assuntos
Feto/anatomia & histologia , Osso Nasal/diagnóstico por imagem , Osso Nasal/embriologia , Ultrassonografia Pré-Natal , Adulto , Aneuploidia , Estudos Transversais , Feminino , Idade Gestacional , Humanos , Gravidez , Primeiro Trimestre da Gravidez , Segundo Trimestre da Gravidez , Estudos Prospectivos , Valores de ReferênciaRESUMO
OBJECTIVE: The purpose of this study was to compare the efficacy and side effects of two different misoprostol regimens for second-trimester pregnancy termination. STUDY DESIGN: We performed a randomized clinical trial in patients who were at 14 to 23 weeks of gestation and who were admitted for medical termination of pregnancy. All patients received 800 microg of vaginal misoprostol and were assigned randomly to 400 microg of oral misoprostol or 400 microg of vaginal misoprostol every 8 hours. Efficacy and side effects were compared. The mean induction time of the study group was compared with that of an historic control group that had received 400 microg vaginally every 12 hours. RESULTS: Forty-three women were assigned randomly, 22 women to vaginal misoprostol and 21 women to oral misoprostol. Induction time and hospital stay were slightly shorter for the oral group; however, the differences were not significant. Side effects were similar for both groups. CONCLUSION: After an initial 800 microg dose of vaginal misoprostol, a regimen of 400 microg of oral misoprostol every 8 hours is as effective as the same dose of vaginal misoprostol with no additional side effects, which provides a convenient alternative for midtrimester pregnancy termination.
Assuntos
Abortivos não Esteroides/administração & dosagem , Aborto Induzido/métodos , Misoprostol/administração & dosagem , Dor Abdominal , Abortivos não Esteroides/efeitos adversos , Administração Intravaginal , Administração Oral , Adulto , Feminino , Idade Gestacional , Humanos , Tempo de Internação , Misoprostol/efeitos adversos , Gravidez , Fatores de Tempo , Falha de TratamentoRESUMO
OBJECTIVE: The purpose of this study was to determine the incidence of velamentous cord insertion and to evaluate the association between velamentous cord insertion and small-for-gestational age infants in triplet gestations. STUDY DESIGN: We reviewed our computerized database to identify all cases of velamentous cord insertion in triplet gestations who were delivered at our institution from January 1995 through December 1999. Triplet gestations without velamentous cord insertion who were delivered during this period were used as control subjects. Birth weights and pregnancy outcomes were obtained from medical records. Data were analyzed with descriptive statistics, analysis of variance, and chi(2) with Fisher exact test, where appropriate. RESULTS: Thirty-nine sets of triplets (117 infants) were delivered during the study period. Of these, 11 sets of triplets (28.2%) had a velamentous insertion of at least one umbilical cord. Infants with velamentous cord insertion were more likely to be small-for-gestational age than infants without velamentous cord insertion (33% vs 8%, P =.02). There were no significant differences in the rates of pregnancy complications between the two groups. CONCLUSION: Velamentous cord insertion is found frequently in triplet gestations and is significantly associated with small-for-gestational age in triplet neonates.